May 28, 2014
Dainippon Sumitomo Pharma (DSP) and Daiichi Sankyo announced on May 26 that the two companies have entered into a license agreement for the commercialization of DSP’s proprietary atypical antipsychotic agent lurasidone HCl in South America. With the deal, Daiichi Sankyo...read more